Disclosures: Strand reports consulting fees from AbbVie, Amgen, AstraZeneca, Biogen, Bristol-Myers Squibb, Celltrion, Corrona, Crescendo, Genentech/Roche, GlaxoSmithKline, Janssen, Eli Lilly & Co., Novartis, Pfizer, Regeneron Pharmaceuticals, Sandoz, Sanofi and UCB. Please see the study for all other authors’ relevant financial disclosures.
November 04, 2020
3 min read
Save

Sarilumab linked to better physical function improvements vs. adalimumab in RA

Disclosures: Strand reports consulting fees from AbbVie, Amgen, AstraZeneca, Biogen, Bristol-Myers Squibb, Celltrion, Corrona, Crescendo, Genentech/Roche, GlaxoSmithKline, Janssen, Eli Lilly & Co., Novartis, Pfizer, Regeneron Pharmaceuticals, Sandoz, Sanofi and UCB. Please see the study for all other authors’ relevant financial disclosures.
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Among patients with rheumatoid arthritis and high baseline interleukin-6, sarilumab was associated with better improvements in physical function and morning stiffness compared with adalimumab, according to data published in Arthritis Research & Therapy.

“The contribution of IL-6 to joint inflammation and bone erosion in RA is well established; however, it has also been associated with non-articular manifestations of RA, including anemia, type 2 diabetes mellitus, and increased cardiovascular risk,” Vibeke Strand, MD, MACR, FACP, of Stanford University, and colleagues wrote. “IL-6 levels also associate with a number of RA-related patient-reported outcomes (PRO), including fatigue and pain.”

Among patients with RA and high baseline IL-6, sarilumab was associated with better improvements in physical function and morning stiffness, compared with adalimumab, according to data. Source: Adobe Stock

“Studies of anti-IL-6R agents, such as tocilizumab and sarilumab, in the treatment of moderate-to-severe RA have revealed the benefits of IL-6 inhibition, not only in the reduction of disease activity, but also improvement in pain and mood disorders associated with RA,” they added. “The value of these clinical and PRO data notwithstanding, a formal association between IL-6 levels and overall health-related quality of life (HRQoL) in RA patients has not been investigated to date.”

To examine whether baseline IL-6 levels can predict health-related quality of life improvements with sarilumab (Kevzara; Regeneron, Sanofi), compared with adalimumab (Humira, AbbVie), Strand and colleagues conducted a post hoc analysis of data from MONARCH, a phase 3, randomized controlled trial. In that study, baseline serum IL-6 levels in 300 out of 369 randomized participants were categorized into low — defined as 1.6 to 7.1pg/mL — medium — 7.2 to 39.5pg/mL — and high — 39.6 to 692.3pg/mL — tertiles.

Vibeke Strand, MD
Vibeke Strand

Among the participants, 148 received sarilumab and 152 were treated with adalimumab. In the sarilumab group, 55 had low IL-6 at baseline, 47 were in the medium tertile and 46 had high levels. Among those treated with adalimumab, 45, 53 and 54 were in the low, medium and high tertiles, respectively.

Health-related quality of life was measured at baseline and then at weeks 24 and 52 using the Short Form 36 (SF-36) physical and mental component summary (PCS/MCS) and domain scores, the Functional Assessment of Chronic Illness Therapy-fatigue, and duration of morning stiffness visual analog scale (VAS). The researchers used a linear regression of changes from baseline in health related quality of life — taking into account IL-6 tertile, treatment, region as a stratification factor, and IL-6 tertile-by-treatment interaction as fixed effects — to determine the predictive native of baseline IL-6, with the low tertile as a reference.

Lastly, Strand and colleagues performed pairwise comparisons of improvements between treatment groups by tertile. In addition, similar analyses evaluated week 24 patient-level response on minimum clinically important differences.

According to the researchers, participants with high, compared with medium or low, IL-6 levels at baseline reported worse (nominal P<.05) SF-36 MCS and role-physical, bodily pain, social functioning, role-emotional domain, and morning stiffness VAS scores. In addition, sarilumab demonstrated a greater treatment effect, compared with adalimumab, among those in the high tertile versus the low tertile in SF-36 PCS, physical functioning domain, and morning stiffness VAS (nominal interaction P<.05).

PCS improvements that reached or exceeded minimum clinically important differences were higher among the high tertile (OR = 6.3; 95% CI, 2.37-16.81), compared with those with low levels of IL-6 (OR = 0.97; 95% CI, 0.43-2.16), with sarilumab versus adalimumab (nominal interaction P<.05). Adverse events were similar between the three tertiles.

“The beneficial effects of sarilumab versus adalimumab on HRQoL were greater in patients with high IL-6 levels at baseline, indicating that among adult RA patients with moderate-to-severely active RA who have had an inadequate response or intolerance to one or more DMARDs, high IL-6 levels may predict greater improvements in PROs/HRQoL than low IL-6 levels,” Strand and colleagues wrote. “These findings support previous analyses which have shown that across various endpoints, patients with elevated baseline IL-6 levels compared with those without responded better to sarilumab compared with methotrexate or adalimumab.”

click me